Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,305 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,823 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03131934 | Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant(ITREC) | completed | Early Phase 1 | 4 | University College, LondonOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT03568994 | Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)(ATACC AML) | completed | Early Phase 1 | 26 | Baylor College of MedicineOTHER | 1 |
| Jun 23, 2026 |
| clinicaltrials |
| NCT03445858 | Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults | completed | Early Phase 1 | 22 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT05895994 | Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies | completed | Early Phase 1 | 2 | MEI HENGOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT03631043 | Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma | completed | Early Phase 1 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT01760226 | Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies(DA-EPOCH-R) | completed | Early Phase 1 | 4 | Baylor College of MedicineOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT04862676 | Repeated HBO Therapy in Myeloma Patients Undergoing High-Dose Therapy and Auto-HCT | completed | Early Phase 1 | 29 | University of RochesterOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT03957915 | Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia(INA03) | completed | Early Phase 1 | 33 | Institut Paoli-CalmettesOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT05049785 | Nutrition and Physical Activity Intervention in Preventing Excess Weight Gain in Pediatric Patients With Leukemia or Lymphoma Treated With Prednisone and/or Dexamethasone | completed | Early Phase 1 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT03295240 | The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma | completed | Early Phase 1 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT01184885 | A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy | completed | Early Phase 1 | 7 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT01822015 | Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Early Phase 1 | 55 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT04628338 | IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation | completed | Early Phase 1 | 8 | Sawa Ito, MDOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT04566978 | 89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL) | completed | Early Phase 1 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT03311958 | Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance | completed | Early Phase 1 | 15 | Fox Chase Cancer CenterOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT06904859 | The Role and Mechanism of TCR-T Cells in Immunotherapy for Acute Myeloid Leukemia | completed | Early Phase 1 | 50 | Shenzhen University General HospitalOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT02921893 | Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome | completed | Early Phase 1 | 21 | Mayo ClinicOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT04689204 | A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies | completed | Early Phase 1 | 3 | He HuangOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT04890236 | Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study | completed | Early Phase 1 | 4 | Emory UniversityOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT05346692 | Digital Meditation for Postoperative Pain Control After Abdominal Surgery for Cancer | completed | Early Phase 1 | 73 | Emory UniversityOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT05923541 | RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies | completed | Early Phase 1 | 6 | Henan Cancer HospitalOTHER_GOV | 1 | Nov 22, 2024 | clinicaltrials |
| NCT05716113 | CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL | completed | Early Phase 1 | 20 | He HuangOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT05902845 | RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL | completed | Early Phase 1 | 4 | Xiaoyu ZhuOTHER_GOV | 1 | Nov 21, 2024 | clinicaltrials |
| NCT04742595 | Viral Specific T Cell Therapy for COVID-19 Related Pneumonia | completed | Early Phase 1 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT02981914 | Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation | completed | Early Phase 1 | 12 | University of ChicagoOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT03771157 | Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors | completed | Early Phase 1 | 33 | University of RochesterOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT05643248 | To Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy Subjects | completed | Early Phase 1 | 9 | Nanexa ABINDUSTRY | 1 | Oct 31, 2023 | clinicaltrials |
| NCT03219047 | Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma | completed | Early Phase 1 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT04484532 | Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers | completed | Early Phase 1 | 130 | Roswell Park Cancer InstituteOTHER | 1 | Jun 6, 2023 | clinicaltrials |
| NCT04518345 | TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia | completed | Early Phase 1 | 3 | Uma BorateOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT03281811 | Photodynamic Therapy in Treating Patients With Refractory Mycosis Fungoides | completed | Early Phase 1 | 11 | Mayo ClinicOTHER | 1 | Jan 5, 2023 | clinicaltrials |
| NCT02851056 | Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT) | completed | Early Phase 1 | 14 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT02405078 | Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma | completed | Early Phase 1 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT02046694 | A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL | completed | Early Phase 1 | 34 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT03825718 | A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL | completed | Early Phase 1 | 29 | Hebei Yanda Ludaopei HospitalOTHER | 1 | Apr 28, 2022 | clinicaltrials |
| NCT01843634 | Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia | completed | Early Phase 1 | 10 | Jazz PharmaceuticalsINDUSTRY | 1 | Nov 10, 2021 | clinicaltrials |
| NCT00424242 | Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases | completed | Early Phase 1 | 15 | Northwestern UniversityOTHER | 1 | Sep 8, 2021 | clinicaltrials |
| NCT02181478 | Intra-Osseous Co-Transplant of UCB and hMSC | completed | Early Phase 1 | 6 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04650724 | Clinical Study of T Cell Infusion Targeting BCMA Chimeric Antigen Receptor | completed | Early Phase 1 | 3 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 3, 2020 | clinicaltrials |
| NCT02331706 | IFN-DLI for Relapsed Acute Leukemia After Allo-SCT | completed | Early Phase 1 | 16 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 21, 2020 | clinicaltrials |
| NCT04321161 | Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm Treatment | completed | Early Phase 1 | 10 | University of FreiburgOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT01239875 | Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma | completed | Early Phase 1 | 16 | Mayo ClinicOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT00013533 | Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies | completed | Early Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT01594242 | Autophagy Induction After Bortezomib for Myeloma | completed | Early Phase 1 | 11 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT01286675 | Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT | completed | Early Phase 1 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 1, 2019 | clinicaltrials |
| NCT02846935 | p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies | completed | Early Phase 1 | 7 | Yogen SaunthararajahOTHER | 1 | Jan 7, 2019 | clinicaltrials |
| NCT00896792 | Nurse Practitioner Hospice Program for Patients With Terminal Metastatic Cancer and Their Families or Caregivers | completed | Early Phase 1 | 26 | Mayo ClinicOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT01719250 | Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Early Phase 1 | 7 | Mayo ClinicOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT01861340 | Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma | completed | Early Phase 1 | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 10, 2018 | clinicaltrials |
Data updated 22 days agoSource updated Aug 7, 2026source: clinicaltrials